S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.95 (+-0.01%)
AAPL   155.07 (-0.57%)
MSFT   257.77 (-0.12%)
META   161.06 (+0.42%)
GOOGL   108.88 (-0.52%)
AMZN   128.85 (-0.49%)
TSLA   285.38 (+0.59%)
NVDA   137.94 (+0.58%)
NIO   17.43 (-0.29%)
BABA   89.52 (-1.19%)
AMD   82.06 (+3.08%)
T   16.83 (-0.24%)
MU   54.87 (-0.24%)
CGC   3.42 (+0.29%)
F   15.19 (-1.56%)
GE   73.52 (-0.08%)
DIS   111.77 (-0.82%)
AMC   8.62 (+2.74%)
PYPL   95.65 (+0.72%)
PFE   46.57 (+0.95%)
NFLX   225.70 (-1.42%)
S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.95 (+-0.01%)
AAPL   155.07 (-0.57%)
MSFT   257.77 (-0.12%)
META   161.06 (+0.42%)
GOOGL   108.88 (-0.52%)
AMZN   128.85 (-0.49%)
TSLA   285.38 (+0.59%)
NVDA   137.94 (+0.58%)
NIO   17.43 (-0.29%)
BABA   89.52 (-1.19%)
AMD   82.06 (+3.08%)
T   16.83 (-0.24%)
MU   54.87 (-0.24%)
CGC   3.42 (+0.29%)
F   15.19 (-1.56%)
GE   73.52 (-0.08%)
DIS   111.77 (-0.82%)
AMC   8.62 (+2.74%)
PYPL   95.65 (+0.72%)
PFE   46.57 (+0.95%)
NFLX   225.70 (-1.42%)
S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.95 (+-0.01%)
AAPL   155.07 (-0.57%)
MSFT   257.77 (-0.12%)
META   161.06 (+0.42%)
GOOGL   108.88 (-0.52%)
AMZN   128.85 (-0.49%)
TSLA   285.38 (+0.59%)
NVDA   137.94 (+0.58%)
NIO   17.43 (-0.29%)
BABA   89.52 (-1.19%)
AMD   82.06 (+3.08%)
T   16.83 (-0.24%)
MU   54.87 (-0.24%)
CGC   3.42 (+0.29%)
F   15.19 (-1.56%)
GE   73.52 (-0.08%)
DIS   111.77 (-0.82%)
AMC   8.62 (+2.74%)
PYPL   95.65 (+0.72%)
PFE   46.57 (+0.95%)
NFLX   225.70 (-1.42%)
S&P 500   3,984.74 (+0.12%)
DOW   31,631.55 (+0.16%)
QQQ   298.95 (+-0.01%)
AAPL   155.07 (-0.57%)
MSFT   257.77 (-0.12%)
META   161.06 (+0.42%)
GOOGL   108.88 (-0.52%)
AMZN   128.85 (-0.49%)
TSLA   285.38 (+0.59%)
NVDA   137.94 (+0.58%)
NIO   17.43 (-0.29%)
BABA   89.52 (-1.19%)
AMD   82.06 (+3.08%)
T   16.83 (-0.24%)
MU   54.87 (-0.24%)
CGC   3.42 (+0.29%)
F   15.19 (-1.56%)
GE   73.52 (-0.08%)
DIS   111.77 (-0.82%)
AMC   8.62 (+2.74%)
PYPL   95.65 (+0.72%)
PFE   46.57 (+0.95%)
NFLX   225.70 (-1.42%)

Vaccine Stocks List

Compare vaccine stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. GILD, JNJ, MRNA, NVAX, PFE).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$65.39
+0.9%
$62.61
$57.17
$74.12
$81.96B0.315.82 million shs275,127 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$163.80
-0.2%
$170.84
$155.72
$186.69
$430.66B0.617.03 million shs61,612 shs
Moderna, Inc. stock logo
MRNA
Moderna
$140.55
+4.2%
$158.85
$115.61
$464.85
$55.91B1.694.25 million shs66,584 shs
Novavax, Inc. stock logo
NVAX
Novavax
$30.13
-1.6%
$49.41
$28.25
$277.80
$2.35B1.654.30 million shs74,337 shs
Pfizer Inc. stock logo
PFE
Pfizer
$46.57
+1.0%
$49.81
$40.94
$61.71
$261.37B0.717.40 million shs278,297 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+2.21%+2.08%+5.18%+5.90%-8.99%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.55%+1.69%-3.60%-5.55%-4.79%
Moderna, Inc. stock logo
MRNA
Moderna
+3.71%+1.99%-26.26%+0.64%-69.09%
Novavax, Inc. stock logo
NVAX
Novavax
+7.33%-7.32%-46.52%-26.18%-88.68%
Pfizer Inc. stock logo
PFE
Pfizer
+0.81%+1.99%-6.94%-10.91%-1.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.51 of 5 Stars
2.13.03.34.11.61.72.5
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.78 of 5 Stars
2.35.04.23.91.62.51.9
Moderna, Inc. stock logo
MRNA
Moderna
2.66 of 5 Stars
3.13.00.04.61.33.32.5
Novavax, Inc. stock logo
NVAX
Novavax
2.60 of 5 Stars
3.35.00.04.71.80.81.9
Pfizer Inc. stock logo
PFE
Pfizer
2.67 of 5 Stars
2.33.04.24.31.81.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.21
Hold$72.4011.01% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$189.8916.33% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.18
Hold$227.7563.72% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.57
Moderate Buy$151.00408.25% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.50
Moderate Buy$57.3323.99% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/7/2022
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$155.00 ➝ $165.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$59.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$59.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/15/2022
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$71.00 ➝ $74.00
8/15/2022
Novavax, Inc. stock logo
NVAX
Novavax
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$110.00
8/9/2022
Novavax, Inc. stock logo
NVAX
Novavax
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$150.00 ➝ $110.00
8/9/2022
Novavax, Inc. stock logo
NVAX
Novavax
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform$150.00 ➝ $110.00
(Data available from 9/8/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.31B2.99$9.22 per share7.07$16.79 per share3.88
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$93.78B4.58$12.76 per share12.79$28.12 per share5.80
Moderna, Inc. stock logo
MRNA
Moderna
$18.47B3.00$32.96 per share4.22$34.89 per share3.99
Novavax, Inc. stock logo
NVAX
Novavax
$1.15B2.03N/AN/A($4.65) per share-6.39
Pfizer Inc. stock logo
PFE
Pfizer
$81.29B3.19$5.48 per share8.44$13.80 per share3.35

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$6.23B$3.2819.8810.320.6515.03%42.92%13.59%10/27/2022 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$20.88B$6.8723.7615.553.1019.21%36.14%14.88%10/18/2022 (Confirmed)
Moderna, Inc. stock logo
MRNA
Moderna
$12.20B$32.814.2417.610.7661.12%94.76%56.65%11/3/2022 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$1.74B-$19.46N/A2.730.07-114.32%-572.54%-55.69%11/3/2022 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$21.98B$5.119.058.560.5628.92%43.18%18.89%11/1/2022 (Estimated)

Latest Vaccine Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/18/2022N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.57N/A-$2.57N/AN/AN/A  
8/8/2022Q2
Novavax, Inc. stock logo
NVAX
Novavax
$5.51-$6.53-$12.04N/A$1.02 billion$186.00 million    
8/3/2022Q2
Moderna, Inc. stock logo
MRNA
Moderna
$4.73$5.24+$0.51N/A$3.95 billion$4.73 billion    
7/28/2022Q2
Pfizer Inc. stock logo
PFE
Pfizer
$1.95$2.04+$0.09N/A$26.20 billion$27.74 billion    
7/19/2022Q2 22
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.57$2.59+$0.02N/A$23.85 billion$24.02 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.924.48%+7.60%89.02%7 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.522.77%+5.78%65.79%61 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.603.46%+4.39%31.31%12 Years

Latest Vaccine Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/2/2022
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.734.85%9/14/20229/15/20229/29/2022
7/18/2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.132.63%8/22/20228/23/20229/6/2022
6/23/2022
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.403.22%7/28/20226/29/20229/6/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.30
1.43
1.27
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.42
1.17
Moderna, Inc. stock logo
MRNA
Moderna
0.04
1.99
1.71
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.99
0.87
Pfizer Inc. stock logo
PFE
Pfizer
0.39
1.42
1.20

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
78.58%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
68.59%
Moderna, Inc. stock logo
MRNA
Moderna
60.76%
Novavax, Inc. stock logo
NVAX
Novavax
42.63%
Pfizer Inc. stock logo
PFE
Pfizer
67.9%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.35%
Moderna, Inc. stock logo
MRNA
Moderna
17.3%
Novavax, Inc. stock logo
NVAX
Novavax
2.1%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
14,4001.25 billion1.25 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
141,7002.63 billion2.62 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
2,700397.76 million328.95 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,54178.14 million76.49 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
79,0005.61 billion5.61 billionOptionable

Vaccine Stocks Headlines

SourceHeadline
Pentagon orders another $4.8B worth of Pfizer’s COVID pills - Herald and NewsPentagon orders another $4.8B worth of Pfizer’s COVID pills - Herald and News
heraldandnews.com - September 8 at 7:57 AM
Alarm over risk of mixing up booster and conventional vaccine - Los Angeles TimesAlarm over risk of mixing up booster and conventional vaccine - Los Angeles Times
latimes.com - September 8 at 2:57 AM
Pfizer to Acquire Australian Digital Health Company for $180 Million - The Epoch TimesPfizer to Acquire Australian Digital Health Company for $180 Million - The Epoch Times
theepochtimes.com - September 8 at 2:57 AM
Pfizer Inc. (PFE) Presents at Citis 17th Annual BioPharma Brokers Conference (Transcript) - Seeking AlphaPfizer Inc. (PFE) Presents at Citi's 17th Annual BioPharma Brokers Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 7 at 9:52 PM
Pfizer (PFE) – Pfizer Whale Trades For September 07 - BenzingaPfizer (PFE) – Pfizer Whale Trades For September 07 - Benzinga
benzinga.com - September 7 at 9:52 PM
FDA Grants Breakthrough Therapy Designation to Pfizers Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - PfizerFDA Grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - Pfizer
pfizer.com - September 7 at 11:50 AM
Pfizer donates Paxlovid to group targeting COVID in poorer countries - ReutersPfizer donates Paxlovid to group targeting COVID in poorer countries - Reuters
reuters.com - September 7 at 11:50 AM
FDA Grants Breakthrough Therapy Designation to Pfizers Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - Business WireFDA Grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - Business Wire
businesswire.com - September 7 at 6:50 AM
Booster jabs in GCC remain ‘critical’ to beat ‘unpredictable’ COVID-19: Pfizer chief - Al Arabiya EnglishBooster jabs in GCC remain ‘critical’ to beat ‘unpredictable’ COVID-19: Pfizer chief - Al Arabiya English
english.alarabiya.net - September 7 at 6:50 AM
COVID: Pfizer, Moderna omicron bivalent boosters confuse providers - USA TODAYCOVID: Pfizer, Moderna omicron bivalent boosters confuse providers - USA TODAY
usatoday.com - September 7 at 6:49 AM
SRHD Supports Recommendation of Pfizer & Moderna Bivalent COVID-19 Boosters | SRHD - Spokane Regional HealthSRHD Supports Recommendation of Pfizer & Moderna Bivalent COVID-19 Boosters | SRHD - Spokane Regional Health
srhd.org - September 7 at 1:49 AM
Heritage Global Partners Awarded New Global Vendor Contract With Pfizer - Business WireHeritage Global Partners Awarded New Global Vendor Contract With Pfizer - Business Wire
businesswire.com - September 6 at 3:48 PM
Pfizer declares special interim dividend of Rs 30 per share - Business StandardPfizer declares special interim dividend of Rs 30 per share - Business Standard
business-standard.com - September 6 at 3:48 PM
Pfizers COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults - Medical Marketing and MediaPfizer's COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults - Medical Marketing and Media
mmm-online.com - September 6 at 3:48 PM
Drug Solutions Podcast: How Pfizer Views Partnering and Investing for Emerging Therapies - Pharmaceutical Technology MagazineDrug Solutions Podcast: How Pfizer Views Partnering and Investing for Emerging Therapies - Pharmaceutical Technology Magazine
pharmtech.com - September 6 at 3:48 PM
Claim that 44% of Pfizer Covid-19 vaccine trial pregnancies ended in miscarriage is wrong - Full FactClaim that 44% of Pfizer Covid-19 vaccine trial pregnancies ended in miscarriage is wrong - Full Fact
fullfact.org - September 6 at 3:48 PM
Israeli research: Myocarditis after Pfizer booster remains rare and mild - The Jerusalem PostIsraeli research: Myocarditis after Pfizer booster remains rare and mild - The Jerusalem Post
jpost.com - September 6 at 3:48 PM
Updated Pfizer and Moderna COVID-19 boosters available at Pandemic Operations Center - Communications and Outreach - Communications and Outreach - North Carolina - New Hanover CountyUpdated Pfizer and Moderna COVID-19 boosters available at Pandemic Operations Center - Communications and Outreach - Communications and Outreach - North Carolina - New Hanover County
news.nhcgov.com - September 6 at 3:48 PM
Shifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, PfizerShifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, Pfizer
gurufocus.com - September 6 at 2:47 PM
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action (Businesswire)Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action (Businesswire)
avanza.se - September 6 at 10:48 AM
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
sg.news.yahoo.com - September 6 at 10:48 AM
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate ActionPfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
finance.yahoo.com - September 6 at 10:48 AM
Pfizer isnt sharing Covid vaccines with researchers for next-gen studies - STATPfizer isn't sharing Covid vaccines with researchers for next-gen studies - STAT
statnews.com - September 6 at 5:47 AM
Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Moderate Buy" from BrokeragesPfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Moderate Buy" from Brokerages
marketbeat.com - September 6 at 2:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.